← All trials
NCT00576407
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2001
- Primary completion
- Feb 1, 2008
- Completion date
- Jun 1, 2027
- First posted
- —
- Last posted
- —
- Enrollment
- 26
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Duke UniversityLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Duke UniversityOverall official - principal investigator
- Duke UniversitySponsor investigator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.